Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
14
06
2019
accepted:
15
10
2019
revised:
14
10
2019
pubmed:
30
10
2019
medline:
22
6
2021
entrez:
30
10
2019
Statut:
ppublish
Résumé
Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibition antibody titres were performed prior to each vaccination and 4 weeks following the final vaccination. A nasopharyngeal aspirate for influenza was performed on participants that developed influenza-like illness. There were 86 children recruited; 43 who had undergone HSCT and 43 controls. For the HSCT group, seroprotection and seroconversion rates were 81.4% and 60.5% for H3N2, 41.9% and 32.6% for H1N1, and 44.2% and 39.5% for B strain respectively. There was a significant geometric mean fold increase to the H3N2 (GMFI 5.80, 95% CI 3.68-9.14, p < 0.001) and B (GMFI 3.44, 95% CI 2.36-5.00, p = 0.048) strains. Serological response was superior in age-matched controls to all vaccine strains. There were no serious adverse events following vaccination. For children who underwent HSCT, incidence of laboratory-proven influenza infection was 2.3%. Overall, this study provides evidence to support annual inactivated influenza vaccine administration to children following HSCT.
Identifiants
pubmed: 31659236
doi: 10.1038/s41409-019-0728-5
pii: 10.1038/s41409-019-0728-5
pmc: PMC7223911
doi:
Substances chimiques
Antibodies, Viral
0
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
773-779Références
Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–84.
doi: 10.1038/sj.bmt.1703139
Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–6.
doi: 10.1086/425004
Fisher BT, Danziger-Isakov L, Sweet LR, Munoz FM, Maron G, Tuomanen E, et al. A multicenter consortium to define the epidemiology and outcomes of inpatient respiratory viral infections in pediatric hematopoietic stem cell transplant recipients. J Pediatr Infect Dis Soc. 2018;7:275–82.
doi: 10.1093/jpids/pix051
Styczynski J, Czyzewski K, Wysocki M, Gryniewicz-Kwiatkowska O, Kolodziejczyk-Gietka A, Salamonowicz M, et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect. 2016;22:179.e1–10.
doi: 10.1016/j.cmi.2015.10.017
Hutspardol S, Essa M, Richardson S, Schechter T, Ali M, Krueger J, et al. Significant transplantation-related mortality from respiratory virus infections within the first one hundred days in children after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1802–7.
doi: 10.1016/j.bbmt.2015.06.015
Lujan-Zilbermann J, Benaim E, Tong X, Srivastava DK, Patrick CC, DeVincenzo JP. Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis. 2001;33:962–8.
doi: 10.1086/322628
Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:94–101.
doi: 10.1016/j.bbmt.2012.08.012
Ryan AL, Kerr F, Gough H, Carter TL, Kotecha RS. Vaccine-preventable disease following allogeneic haematopoietic stem cell transplant in Western Australia. J Paediatr Child Health. 2019;55:343–8.
doi: 10.1111/jpc.14204
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.
doi: 10.1093/cid/cit816
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–12.
doi: 10.1016/S1473-3099(18)30600-5
Dulek DE, de St Maurice A, Halasa NB. Vaccines in pediatric transplant recipients-past, present, and future. Pediatr Transplant. 2018;22:e13282.
doi: 10.1111/petr.13282
Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook, 10th Ed. Canberra: Australian Government Department of Health, 2013.
WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza, 2011. Available from URL: https://www.who.int/influenza/gisrs_laboratory/manual_diagnosis_surveillance_influenza/en/ . Accessed 8th May 2019.
Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin S, Orenstein W, Offit PA (eds). Vaccines, 6th Ed. Philadelphia, PA: Elsevier 2013; pp 257–93.
Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. European Agency for the Evaluation of Medicinal Products (EMEA). March 1997.
Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr. 1997;130:388–93.
doi: 10.1016/S0022-3476(97)70200-2
Yalcin SS, Kondolot M, Albayrak N, Altas AB, Karacan Y, Kuskonmaz B, et al. Serological response to influenza vaccine after hematopoetic stem cell transplantation. Ann Hematol. 2010;89:913–8.
doi: 10.1007/s00277-009-0897-1
Haining WN, Evans JW, Seth NP, Callaway GD, Wucherpfennig KW, Nadler LM, et al. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol. 2004;127:322–5.
doi: 10.1111/j.1365-2141.2004.05204.x
Guerin-El Khourouj V, Duchamp M, Krivine A, Pedron B, Ouachee-Chardin M, Yakouben K, et al. Cellular and humoral immunity elicited by influenza vaccines in pediatric hematopoietic-stem cell transplantation. Hum Immunol. 2012;73:884–90.
doi: 10.1016/j.humimm.2012.07.039
Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 2008;86:257–63.
doi: 10.1097/TP.0b013e3181772a75
Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.
pubmed: 8431706
Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013;19:109–16.
doi: 10.1016/j.bbmt.2012.08.015
Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29:1777–82.
doi: 10.1016/j.vaccine.2010.12.113
de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96:307–14.
doi: 10.3324/haematol.2010.032664
Gueller S, Allwinn R, Mousset S, Martin H, Wieters I, Herrmann E, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1546–50.
doi: 10.1016/j.bbmt.2011.02.004
Mohty B, Bel M, Vukicevic M, Nagy M, Levrat E, Meier S, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96:896–904.
doi: 10.3324/haematol.2011.040386
Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36:897–900.
doi: 10.1038/sj.bmt.1705159
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.
doi: 10.1016/j.bbmt.2009.06.019